Latest Healthcare News

Anteris Technologies has secured its first European regulatory clearance to commence the global PARADIGM Trial for its DurAVR Transcatheter Heart Valve, marking a significant step toward worldwide commercialization.

Clarity Pharmaceuticals has inked a pivotal supply agreement with Nusano to ensure a steady source of copper-67, a critical isotope for its upcoming Phase III prostate cancer trial and future commercialisation plans.

Cogstate Limited reports a record-breaking quarter with sales contracts soaring 88% year-on-year, driven by expanding markets and new therapeutic areas. The company signals continued investment in growth initiatives, including AI and Asia-Pacific expansion, while projecting a strong first half of FY26.

Audeara Limited has landed its maiden purchase order for hearing aid technology in China, marking a pivotal step in its global expansion with production and launch planned for the final quarter of 2025.

Beamtree Holdings has reported a 9% increase in recurring revenue for Q1 FY26, driven by strong contract wins and international expansion, including a key UK NHS partnership and a new autonomous coding rollout.

Proteomics International has expanded its partnership with the University of Melbourne and Royal Women’s Hospital to further validate and develop its PromarkerEndo blood test, aiming to revolutionize endometriosis diagnosis.

Bank of Queensland reported a robust FY25 with 12% growth in cash earnings and significant progress in its digital banking and branch conversion initiatives. The bank’s focus on productivity and specialist business lending underpins its optimistic outlook despite ongoing economic uncertainties.

Argenica Therapeutics reports encouraging functional improvements in stroke patients treated with ARG-007, setting the stage for a targeted Phase 2b trial focused on patient-centered outcomes.

Telix Pharmaceuticals reports a robust 53% revenue jump in Q3 2025 and raises its full-year guidance, underpinned by key reimbursement wins and expanding clinical programs.

333D Ltd reports a fifth consecutive quarter of revenue growth, secures $1 million in fresh capital, and expands its blockchain healthcare initiatives while building a strategic Bitcoin treasury.

Clarity Pharmaceuticals’ Co-PSMA Phase II trial shows its Cu-SAR-bisPSMA diagnostic agent detects more prostate cancer lesions than current standard imaging, promising earlier and more accurate recurrence detection.

EMVision Medical Devices has received a $3 million government grant to fund a clinical study demonstrating its emu™ brain scanner's impact on accelerating stroke diagnosis in rural emergency departments.